CN107281572A - Blood purification system - Google Patents
Blood purification system Download PDFInfo
- Publication number
- CN107281572A CN107281572A CN201610471829.9A CN201610471829A CN107281572A CN 107281572 A CN107281572 A CN 107281572A CN 201610471829 A CN201610471829 A CN 201610471829A CN 107281572 A CN107281572 A CN 107281572A
- Authority
- CN
- China
- Prior art keywords
- blood
- plasma
- cytohormone
- purification system
- absorber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 123
- 239000008280 blood Substances 0.000 title claims abstract description 123
- 238000000746 purification Methods 0.000 title claims abstract description 63
- 239000000463 material Substances 0.000 claims abstract description 50
- 238000001179 sorption measurement Methods 0.000 claims abstract description 40
- 210000000601 blood cell Anatomy 0.000 claims abstract description 30
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 10
- 239000012510 hollow fiber Substances 0.000 claims abstract description 5
- 210000002381 plasma Anatomy 0.000 claims description 91
- 239000006096 absorbing agent Substances 0.000 claims description 53
- 150000001875 compounds Chemical class 0.000 claims description 41
- 239000011347 resin Substances 0.000 claims description 35
- 229920005989 resin Polymers 0.000 claims description 35
- 238000002156 mixing Methods 0.000 claims description 28
- 238000010521 absorption reaction Methods 0.000 claims description 27
- 210000004027 cell Anatomy 0.000 claims description 20
- 239000005556 hormone Substances 0.000 claims description 15
- 229940088597 hormone Drugs 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 239000003957 anion exchange resin Substances 0.000 claims description 11
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 5
- 238000001631 haemodialysis Methods 0.000 claims description 4
- 239000002002 slurry Substances 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 1
- MYRTYDVEIRVNKP-UHFFFAOYSA-N divinylbenzene Substances C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims 1
- 239000003456 ion exchange resin Substances 0.000 claims 1
- 229920003303 ion-exchange polymer Polymers 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 abstract description 6
- 108090000695 Cytokines Proteins 0.000 abstract description 6
- 239000002131 composite material Substances 0.000 abstract 2
- 210000004180 plasmocyte Anatomy 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 description 29
- 239000002158 endotoxin Substances 0.000 description 28
- 238000005516 engineering process Methods 0.000 description 27
- 108090001005 Interleukin-6 Proteins 0.000 description 24
- 102000004889 Interleukin-6 Human genes 0.000 description 24
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 24
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 24
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 23
- 108010088751 Albumins Proteins 0.000 description 23
- 102000009027 Albumins Human genes 0.000 description 23
- 208000013223 septicemia Diseases 0.000 description 23
- 238000012360 testing method Methods 0.000 description 19
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 18
- 230000002000 scavenging effect Effects 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 16
- 102000003814 Interleukin-10 Human genes 0.000 description 15
- 108090000174 Interleukin-10 Proteins 0.000 description 15
- 241000282898 Sus scrofa Species 0.000 description 15
- 108090001007 Interleukin-8 Proteins 0.000 description 14
- 102000004890 Interleukin-8 Human genes 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 102000003777 Interleukin-1 beta Human genes 0.000 description 12
- 108090000193 Interleukin-1 beta Proteins 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 238000000502 dialysis Methods 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 230000004087 circulation Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000003463 adsorbent Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 239000002699 waste material Substances 0.000 description 5
- 238000008157 ELISA kit Methods 0.000 description 4
- 208000034486 Multi-organ failure Diseases 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 238000005349 anion exchange Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000002651 drug therapy Methods 0.000 description 4
- 230000000004 hemodynamic effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 239000002156 adsorbate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 3
- 229960001008 heparin sodium Drugs 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000012089 stop solution Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000010718 Multiple Organ Failure Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 230000009692 acute damage Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 108010008250 drotrecogin alfa activated Proteins 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000007234 antiinflammatory process Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000003918 blood extract Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000000805 composite resin Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 229960000209 drotrecogin alfa (activated) Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- 230000009097 homeostatic mechanism Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 244000309715 mini pig Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920003053 polystyrene-divinylbenzene Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3607—Regulation parameters
- A61M1/3609—Physical characteristics of the blood, e.g. haematocrit, urea
- A61M1/3612—Physical characteristics of the blood, e.g. haematocrit, urea after treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3627—Degassing devices; Buffer reservoirs; Drip chambers; Blood filters
- A61M1/3633—Blood component filters, e.g. leukocyte filters
- A61M1/3635—Constructional details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3643—Priming, rinsing before or after use
- A61M1/3644—Mode of operation
- A61M1/3649—Mode of operation using dialysate as priming or rinsing liquid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3687—Chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3692—Washing or rinsing blood or blood constituents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
- B01J20/261—Synthetic macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2220/00—Aspects relating to sorbent materials
- B01J2220/40—Aspects relating to the composition of sorbent or filter aid materials
- B01J2220/44—Materials comprising a mixture of organic materials
- B01J2220/445—Materials comprising a mixture of organic materials comprising a mixture of polymers
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- External Artificial Organs (AREA)
Abstract
A blood purification system comprises a plasma separator, a cytokine adsorber and a hemodialyzer, wherein the plasma separator is provided with a first column and a plurality of hollow fiber bundles filled in the column and is used for separating plasma from a plurality of blood cells in blood extracted from a human body; the cytokine adsorber is provided with a second column and a composite adsorption material arranged in the second column, and the composite adsorption material is used for adsorbing part of pathogenic cytokine in the plasma to obtain purified plasma; and a hemodialyzer for dialyzing the mixed blood (purified plasma and blood cells) to obtain clean blood.
Description
Technical field
The present invention is to disclose a kind of blood purification system, in particular to being used to adsorb blood using compound sorbing material
Pathogenic cell hormone or excessive cytohormone in slurry, with the blood after being purified, and by blood circulation the Huis' body of purification
Internal blood purification system.
Background technology
According to statistics, septicemia causes serious multiple organ's exhaustion (Multiple organ failure, MOF) fatal rate
Up to 30%-60%.In the U.S., septicemia patient year in 2011 has exceeded a million people, and with year multiple growth rate
2.42% speed increase, and each year, because the dead number of septicemia is more than 210,000 5 thousand people, the medical institutions in the U.S. are every
Spend within 1 year and look after nearly 17,000,000,000 dollars of septicemia sufferer, be similarly up in the market of European Union's septicaemia treatment in each year
7600000000 Euros, therefore septicemia turns into one of disease for the treatment of cost most expensive.According to statistics, the whole world has up to 1 within each year,
8000000 people suffer from septicemia, and the death rate is up to 28%-50%.In TaiWan, China, the statistics of Department of Health's (now claiming ministry of Health and Welfare)
Report, consultation rate of being in hospital in 2006 years is every 100,000 368 people, and convert the people of sufferer about 70,000 6 thousand, dead in 2008 years TaiWan, Chinas
Be up to 3,534 people in septicemic cemia sufferer, wherein women die ranking has reached the 9th, many counties and cities final ranking all
Discharge into top 10.Go all out to put into the research and development of septicaemia treatment invariably in huge medical treatment and the market demand just because of this, countries in the world.
Septicemia is looked after medical association (ACCP/SCCM) by U.S.'s chest medicine meeting/severe and is defined as because of infection (bacterium, disease
Poison, mould or parasitic animal and plant) caused by systemic inflammatory reaction syndrome (Systemic Inflammatory Response
Syndrome,SIRS).Septicemia (Sepsis) is clinically the reason for causing patient's quick death.Its feature is simultaneously
There are infective micro-organisms (bacterium, virus or fungi) and the reaction of systemic inflammation disease.About 25%-30% septicemia is suffered from
Person can develop into serious multiple organ's exhaustion (Multiple organ failure, MOF), and fatal rate reaches 30%-60%.Work as body
Body declines to antimicrobial ability, will easily be infected, and easily occurs immunologic dysfunction, for example aging, AIDS,
Cytotoxic drug and immunosuppressive drug, malnutrition, excessive drinking, malignant tumour, diabetes are taken, exposed to resistance to the action of a drug cause of disease
In the environment of increase and the situation such as aggressive diagnosis and treatment.
After occurring systemic inflammation reaction syndrome (SIRS), the anti-inflammatory for triggering compensatory is reacted.This mistake
Exotic mediums stimulate cell to journey before this, disengage a variety of different cytohormones (Cytokine) and cause excessive buildup interleukins
6 (hereinafter referred to as IL-6), interleukin 10 (hereinafter referred to as IL-10) and tumor necrosis factor-alpha (hereinafter referred to as TNF-α) phenomenon.This
Phenomenon triggers successional violent inflammatory response:, ischemic/reperfusion not enough from primary cellular damage to tissue perfusion damage to
Disseminated intravascular coagulation triggers periphery blood vessel dilatation, diffusivity blood vessel to/immune/inflammation/adventitious agents reciprocation is circulated
Intravascular coagulation (DIC) etc., finally results in systemic multiple organ's exhaustion.Clinically also confirm that in septic shock (Septic
Shock) IL-6 numerical value is up to 7,500 times of normal person unexpectedly with patient.Therefore, how effectively to be removed in the circulatory system
The cytohormone of amount exactly clinically compels to be essential at present come the immunologic mechanism reformed Homeostatic mechanism and recover normal physiological
The problem of solving.
Correlative study is had at present and removes cytohormone using absorber or dialyzer, can slow down organ failure's
Situation.In prior art, WiwatChancharoenthana uses the mode of hemodiafiltration
(Hemodiafiltration, HDF), with high penetration haemodialysis (High flux hemodialysis) Randomized treatment 28
Septicemia Associated Acute injury of kidney (sepsis-related acute kidney injury) sufferer, as a result shows that HDF can be bright
It is aobvious remove VEGF (vascular endothelial growth factor, VEGF, hereinafter referred to as VEGF),
The cytohormone such as IL-6, IL-10 and TNF-α, renal function recovers preferable.Separately there is prior art, HP Shun are acute for 6
Impaired renal patient, has carried out clinic using the patient of Blood index filter and 24 historical control groups and has compared, be as a result shown in leather
In acute injury of kidney patient caused by gram-negative bacteria infection, after 48 hours treat, patient organ's exhaustion scoring substantially subtracts
Few 37%, relatively conventional continuity Venous Hemofiltration, endotoxin and cell factor absorption blood filtration are not only safe, can more add
It is fast to improve organ dysfunction.
The content of the invention
For prior art, because the selectivity polymeric adsorbent cost of single cell hormone (Cytokine) is too high, and carefully
Intracellular hormone species is various, and indivedual exploitation selectivity resins do not meet economic benefit.For this situation.Due to cytohormone molecular weight
About slightly 8KDa-30KDa protein or glycoprotein, it is a primary object of the present invention to non-specific and with quite selection
Property polymeric adsorbent be target, research and develop adsorbable various kinds of cell hormone and avoid adsorbing other albumen or a variety of useful simultaneously
The resin of material, can be effectively reduced medical treatment cost, the replacement therapy method of such acute severe is easy to popularization and add favour needs
Sufferer.
Another object of the present invention is to provide a kind of compound sorbing material, swash for the pathogenic cell in adsorbed plasma
Plain or excessive cytohormone, with the blood plasma after being purified.
A further object of the present invention is using uncharged resin and electrically charged anion exchange resin with ratio
Compound sorbing material is formed after mixing and is inserted in tubing string, is adsorbed and is reached for the pathogenic cell hormone in blood plasma
Purify the effect of blood.
According to above-mentioned purpose, the invention discloses a kind of blood purification system, comprising:Plasma separator, cytohormone absorption
Device and haemodialyser, wherein plasma separator have first tubing string and the multiple hollow fiber bundles being filled in first tubing string,
The purpose of plasma separator is the blood plasma in the blood extracted by human body to be separated with multiple blood cells；Cytohormone is inhaled
Adnexa has second tubing string and the compound sorbing material being placed in second tubing string, and cytohormone absorber utilizes compound absorption
Material is adsorbed the pathogenic cell hormone of blood plasma partial to be purified blood plasma, wherein compound sorbing material by without
The resin of electric charge and electrically charged anion exchange resin composition；And haemodialyser, adsorbed to receive by cytohormone
The purification blood plasma that device is conveyed mixes blood with via the separated blood cell of plasma separator is mixed, and utilizes dialyzer pair
Mixing blood further gives the waste or medicine remained in blood, thereby obtains clean blood, and will can do
In net blood circulation the Huis' body body.
Coordinate disclosed herein blood purification system, the present invention also disclose a kind of blood purification method, include step
Have:Blood is provided；Blood is separated to obtain blood plasma and multiple blood cells；Adsorption step is carried out to blood plasma, to remove causing a disease in blood plasma
Cytohormone, to be purified blood plasma；Purification blood plasma is mixed with blood cell to form mixing blood；And carry out mixing blood
Dialysis, to obtain clean blood.Therefore, either blood purification system or blood purification method can be avoided in existing skill
In art, during using drug therapy, due to internal complicated pharmacokinetics and pharmacological mechanism, derivative many side effects.
Brief description of the drawings
Fig. 1 be according to disclosed herein technology, represent blood purification system schematic diagram.
Fig. 2 be according to disclosed herein technology, represent blood purification system block schematic diagram.
Fig. 3 be according to disclosed herein technology, represent blood purification flow chart of steps.
Fig. 4 be according to disclosed herein technology, represent have uncharged resin and electrically charged anion exchange
Mixed with resin ratio is 20%:Absorption of 80% (v/v) the compound sorbing material to the Scavenging activity of various cytohormones is bent
Line chart.
Fig. 5 be according to disclosed herein technology, represent have uncharged resin and electrically charged anion exchange
Mixed with resin ratio is 40%:Absorption of 60% (v/v) the compound sorbing material to the Scavenging activity of various cytohormones is bent
Line chart.
Fig. 6 be according to disclosed herein technology, represent have uncharged resin and electrically charged anion exchange
Mixed with resin ratio is 60%:Adsorption curve of 40% (v/v) the compound sorbing material to the removing solid capacity of various cytohormones
Figure.
Fig. 7 be according to disclosed herein technology, represent have uncharged resin and electrically charged anion exchange
Mixed with resin ratio is 80%:Absorption of 20% (v/v) the compound sorbing material to the Scavenging activity of various cytohormones is bent
Line chart.
Fig. 8 be according to disclosed herein technology, represent cytohormone absorber to adsorb p-cresol removing energy
The adsorption time of power and the adsorption curve figure of clearance rate.
Fig. 9 be according to disclosed herein technology, represent cytohormone absorber to the Scavenging activity of cytohormone
Adsorption curve figure.
Figure 10 be according to disclosed herein technology, represent suction of the cytohormone absorber to IL-1 β Scavenging activity
Attached curve map.
Figure 11 be according to disclosed herein technology, represent absorption of the cytohormone absorber to IL-6 Scavenging activity
Curve map.
Figure 12 be according to disclosed herein technology, represent absorption of the cytohormone absorber to IL-8 Scavenging activity
Curve map.
Figure 13 be according to disclosed herein technology, represent suction of the cytohormone absorber to IL-10 Scavenging activity
Attached curve map.
Figure 14 be according to disclosed herein technology, represent suction of the cytohormone absorber to the Scavenging activity of TNF-α
Attached curve map.
Figure 15 be according to disclosed herein technology, there is shown removing energy of the cytohormone absorber to endotoxin
The adsorption curve figure of power.
Figure 16 be according to disclosed herein technology, represent zoopery during synchronously carry out hemodynamic monitoring
As a result curve map.
Figure 17 be according to disclosed herein technology, represent non-endotoxin injection and only carry out the animal examination of blood purification
Test the curve map of (Hemopurification alone groups) result.
Figure 18 be according to disclosed herein technology, represent TNF-α dialysis initial stage its concentration curve descending slope and
Amplitude just has obvious increased curve map.
Figure 19 be according to disclosed herein technology, represent IL-6 in dialysis its concentration curve descending slope and width at initial stage
Degree just has obvious increased curve map.
Figure 20 be according to disclosed herein technology, represent the pass of (L+H (new) group) in the test of cytohormone absorber
System's figure.
Embodiment
In order that the purpose of the present invention, technical characteristic and advantage, can more correlative technology field personnel understood, and be able to
Implement the present invention, appended schema is coordinated herein, the technical characteristic and embodiment of the present invention is specifically illustrated, and enumerates preferable reality
Example is applied to further illustrate.With the schema hereinafter compareed, to express the signal relevant with feature of present invention, also need not
Completely drawn according to practical situation.And it is related to technology well-known to those skilled in the art in the explanation on this case embodiment
Content, is also no longer stated.
Blood purification system applies the removal of uremic in blood, that is, " the washing kidney " being widely known by the people.Its principle is will
Blood extracts external out, after material harmful in the program removal blood such as dialysis or absorption, recycles ex vivo
It is interior.It is that the small molecule toxins in blood, such as urea or creatine liver are removed using the dialysis function of pellicle for example to wash kidney
Etc. (creatinine) with excessive moisture content in removing body.Same concept can be applied to the treatment of septicemia, its operation principle be by
After blood is extracted out in vitro, blood cell is separated with blood plasma using plasma separator, cytohormone absorber is recycled by blood plasma
Excessive cytohormone (Cytokine) Adsorption, then by treated blood plasma with blood cell mixing Posterior circle ex vivo.By
Blood purification system can be with cytohormone excessive in removing body, compared to drug therapy is utilized, due to internal complicated medicine
Dynamics and pharmacological mechanism, can often derive many side effects, such as Human Active's albumen c (drotrecogin-alfa
(activated), rhAPC) derived from bleeding reaction.But according to disclosed herein blood purification system without by body
Intracellular metabolite, therefore without related misgivings.Therefore disclosed herein blood purification system can be shared even with drug therapy
Supply drug therapy weak point.Below for disclosed herein blood purification system explain.
Referring first to Fig. 1.Fig. 1 be according to disclosed herein technology, represent blood purification system schematic diagram.In figure
In 1, blood purification system 1 includes plasma separator 10, cytohormone absorber 20 and haemodialyser 30, wherein, blood plasma point
Communicated with each other respectively with cytohormone absorber 20 and haemodialyser 30 with blood circuit sleeve pipe group 40 from device 10.In addition,
Valve member (valve) (the not table in figure is additionally provided between plasma separator 10, cytohormone absorber 20 and haemodialyser 30
Show), this valve member is worked as in fluid (blood, blood plasma or blood cell) in plasma separator 10, cytohormone absorber 20 and blood
Opening to close when conveying between dialyzer 30 allows fluid to input or export these devices.
Similarly, please continue to refer to Fig. 1.Plasma separator 10, the separation to separate blood plasma and blood cell in blood is filled
Put, plasma separator 10 is mainly made up of tubing string 12 and the multiple hollow fiber bundles 14 being placed in tubing string 12.In this hair
It is bright, it is necessary to which accurately control filtering pore size, caliber and pipe thickness, can just efficiently separate blood plasma and blood cell, and accord with
Close the stream power demand of the operating process of separation.It is noted that because blood is viscous fluids, can not be caused in operating process
Excessive pressure drag, can must on demand control blood to enter the flow of plasma separator 10, and to avoid blood from being separated in blood plasma
Blood coagulation phenomenon occurs in device 10.
Cytohormone absorber 20, for adsorbing with remove in blood plasma cause a disease cytohormone adsorbent equipment.Cell swashs
Plain absorber 20 is mainly made up of tubing string 22 and compound sorbing material 24, wherein the main mesh of compound sorbing material 24
Be the pathogenic cell hormone or excessive cytohormone that can be adsorbed in blood plasma, and its adsorption capacity is at least greater than
65%, and used compound sorbing material 24 cannot albumen necessary to human body in adsorbed plasma, for example:Albumin
(albumin), compound sorbing material 24 is less than 15% to the adsorption capacity of albumin.In addition, for adherent cell hormone
Compound sorbing material 24 there is high specific surface area, to provide enough adsorption areas, and with appropriate particle diameter with
Intensity, with the pressure produced by resisting in operation, can thereby be avoided in cytohormone absorber 20 because excessive is carried
Boosting resistance, and cause the damaged or whole cytohormone absorber 20 of compound sorbing material 24 to be damaged because pressure is excessive, and
It can not operate.
In the present invention, cause a disease as absorption or excessive cytohormone compound sorbing material 24 at least by two kinds
Resin is constituted, including uncharged resin and electrically charged anion exchange resin, wherein, uncharged resin be styrene-
Divinylbenzene resins (poly (styrene-divinylbenzene, PS-DVB)), chemical structural formula isThe physical characteristics of materials of styrene-divinyl benzene resin:Particle diameter is 75um-
106um, specific surface area are 560m2/ g, porosity (pore size) areOperation temperature is 130 DEG C and electrically charged
Anion exchange resin is styrene-divinyl benzene resin level Four ammonium, Cl types (poly (styrene-divinylbenzene) four
Level ammonium, Cl types), its chemical structural formula is
The physical characteristics of materials of electrically charged anion exchange resin:
Particle diameter is more than or is more than at least equal to 450um, exchange capacity or at least equal to 80 DEG C of 0.85 (meq/ml-R), operation temperature.
In embodiments of the invention, uncharged resin and electrically charged anion exchange resin are mixed with shape in varing proportions
Into composite resin, such as uncharged resin:Electrically charged anion exchange resin can mixing ratio be 20%:80% (v/
V), 40%:60 (v/v), 60%:40% (v/v) or 80%:20% (v/v).
Then, first isolated by-the blood plasma that is purified by cytohormone absorber 20 and in plasma separator 10
Haemodialyser 30 is entered back into after blood cell mixing and carries out haemodialysis step, to obtain clean blood and be recycled back to human body
It is interior.Haemodialyser 30 mainly contains the multiple small hollow fibres (being represented not in figure) made by artificial pellicle,
And allow liquid (blood) to be flowed between these small hollow fibres, and have clean dialyzate outside hollow fibre (not
Represented in figure) enter via the dialyzate entrance 302 of haemodialyser 30, and the waste or medicine allowed in blood via
The mode of dialysis and separate out, it is and 304 the dialyzate containing waste or medicine is defeated by the dialyzate outlet of haemodialyser 30
Go out, to reach using haemodialyser 30 come the toxin expelling work of temporary transient or permanent substitution patient renal.
Then, it please also refer to Fig. 2 and Fig. 3.Fig. 2 according to disclosed herein technology, represent blood purification system
Block schematic diagram and Fig. 3 according to disclosed herein technology, represent blood purification flow chart of steps.First, coordinate Fig. 2's
Blood purification system, the present invention also discloses blood purification method, has comprising step:Blood is provided；Separate blood with blood plasma and
Multiple blood cells；Adsorption step is carried out to blood plasma, to remove the pathogenic cell hormone in blood plasma, to be purified blood plasma；Will purification
Blood plasma mixes to form mixing blood with blood cell；And mixing blood is dialysed, to obtain clean blood.Detailed step is such as
Step 60 to step 70, wherein step 60 is to extract blood out in human body 50 using blood side Pu (pump) 5 in Fig. 3, specific next
Say it is by human body 50 using blood side Pu 5 via syringe needle (being represented not in figure) and blood circuit pipeline 40 (as shown in Figure 1)
Artery in extract blood out.Then, step 62, blood is delivered to plasma separator 10, using plasma separator 10 by blood
In blood cell and blood plasma separation.In this step 62, the blood extracted out in the artery of human body 50 can be via blood circuit pipe
Line 40 delivers into plasma separator 10, and using the hollow fiber bundle 12 (as shown in Figure 1) in plasma separator 10 by blood
Blood plasma and blood cell in liquid are separated from each other.Step 64, cytohormone absorber 20 will be delivered to by the blood plasma of separation, using thin
Excessive cytohormone and/or cause in compound sorbing material 24 (as shown in Figure 1) adsorbed plasma in intracellular hormone absorber 20
Sick cytohormone, to be purified blood plasma.In this step 64, due to the material property of compound sorbing material 24, Jin Jinzhen
Pathogenic cell hormone and/or excessive cytohormone in blood plasma is adsorbed, without being carried out to the albumin in blood plasma
Absorption, therefore the purification blood plasma still presence containing albumin produced by after absorption.
Then, such as step 66, the blood cell after purifying blood plasma and being separated through plasma separator 10 is mixed to form mixing blood
After liquid (purification blood plasma and blood cell mixed liquor), haemodialyser 30 is delivered into.In this step, it will be inhaled by cytohormone
After adnexa 20 is adsorbed, resulting purification blood plasma is with passing through the blood cell after plasma separator 10 is separated in blood to be delivered into
Before liquid dialyzer 30, first mixed to form mixing blood (purification blood plasma and blood cell mixed liquor), blood is then inputted again
Dialyzer 30, this blend step can be mixed in the blood circuit pipeline 40 before entering haemodialyser 30, or
Mixing arrangement (being represented not in figure) is set to mix purification blood plasma and blood cell in addition, it is unlimited to this in the present invention
System.And then, step 68 is carried out, will mix blood (purification blood plasma and blood cell mixed liquor) using haemodialyser 30 is carried out thoroughly
Analysis.In this step, due to still remaining some wastes or medicine in mixing blood (purification blood plasma and blood cell mixed liquor), it is
This mixing blood (purification blood plasma and blood cell mixed liquor) of further purification, therefore in whole extracorporeal circulation system, utilize blood
Liquid dialyzer 30, and dialyzate (is represented) not in figure in injection haemodialyser 30, for mixing blood (purification blood plasma
With blood cell mixed liquor) carry out dialysis step, allow in mixing blood (purification blood plasma with blood cell mixed liquor) may residual medicine or
It is that waste is separated out via dialyzate and discharged by haemodialyser 30, to obtain clean blood.Finally, step 70, it will pass through
Clean blood output after dialysis, then via in venous circulation the Huis' body of human body.
Therefore, for disclosed herein compound sorbing material, in varing proportions, such as 20%:80% (v/v),
40%:60 (v/v), 60%:40% (v/v) or 80%:20% (v/v) uncharged resin and electrically charged anion are handed over
Change mixed with resin and form compound sorbing material, to carry out the composition and cytohormone adsorption effect of compound sorbing material
Experiment, wherein table 1 are to represent that mixing ratio is 20%:80% (v/v) compound sorptive material to the clearance rate of cytohormone,
Table 2 is to represent that mixing ratio is 40%:60% (v/v) compound sorptive material is to represent to the clearance rate of cytohormone, table 3
Mixing ratio is 60%:40% (v/v) compound sorptive material is to represent mixing ratio to the clearance rate and table 4 of cytohormone
For 80%:Clearance rate of 20% (v/v) the compound sorptive material to cytohormone.
Table 1 (20%:80% (v/v))
| TNF-α | IL-1β | IL-6 | IL-8 | IL-10 | |
| 0h | 0 | 0 | 0 | 0 | 0 |
| 0.5h | 76.72 | 74.42 | 68.23 | 56.65 | 58.67 |
| 1h | 78.85 | 74.80 | 71.18 | 63.34 | 62.97 |
| 2h | 77.90 | 75.26 | 71.80 | 59.99 | 62.06 |
| 3h | 78.77 | 73.56 | 71.20 | 62.75 | 59.08 |
| 4h | 79.79 | 75.75 | 70.56 | 64.16 | 60.77 |
| 5h | 79.79 | 69.89 | 67.80 | 63.34 | 59.31 |
Table 2 (40%:60% (v/v))
| TNF-α | IL-1β | IL-6 | IL-8 | IL-10 | |
| 0h | 0 | 0 | 0 | 0 | 0 |
| 0.5h | 9.06 | 25.33 | 28.90 | -27.74 | 43.11 |
| 1h | 15.75 | 19.61 | 50.87 | 20.88 | 42.60 |
| 2h | 19.87 | 37.35 | 52.71 | 25.23 | 49.23 |
| 3h | 15.37 | 41.11 | 43.95 | 18.02 | 48.78 |
| 4h | 20.08 | 39.22 | 55.64 | 20.09 | 48.14 |
| 5h | 21.79 | 38.69 | 60.63 | 6.86 | 47.81 |
Table 3 (60%:40% (v/v))
Table 4 (80%:20% (v/v))
| TNF-α | IL-1β | IL-6 | IL-8 | IL-10 | |
| 0h | 0 | 0 | 0 | 0 | 0 |
| 0.5h | 53.33 | 42.04 | 55.94 | 40.13 | 49.00 |
| 1h | 59.93 | 49.75 | 55.98 | 48.32 | 57.68 |
| 2h | 58.67 | 49.12 | 64.25 | 53.70 | 57.55 |
| 3h | 57.40 | 50.34 | 64.33 | 50.21 | 52.38 |
| 4h | 57.76 | 50.60 | 61.76 | 47.56 | 55.40 |
| 5h | 56.44 | 45.87 | 58.35 | 50.64 | 53.40 |
And Fig. 4 to Fig. 7 represents the compound sorbing material of different mixing proportion for the clear of various cytohormones respectively
The curve map of removing solid capacity.It can be obtained, be handed in uncharged resin and electrically charged anion from table 1-4 Fig. 4 with to Fig. 7
The mixing ratio for changing resin is 60%:When 40%, come for the Scavenging activity of various cytohormones than other mixed proportions
It is high.
Therefore, in order to prove disclosed herein blood purification system 1 for current medical industries, particularly blood
Dialysis has suitable contribution, for blood purification system 1 to TNF-α, IL-1 β, IL-6, IL-10, endotoxin, p-cresol
Adsorption capacity, absorption albumin (albumin) carry out adsorption test and cell toxicant test with removing thing total amount etc., and according to upper
State using the data obtained by the uncharged resin of different mixing proportion and electrically charged anion exchange resin, in following reality
In testing, the mixed proportion with preferable Scavenging activity is used for 60%:40% (v/v) (uncharged resin:It is electrically charged it is cloudy from
Sub-exchange resin) compound sorbing material 24 be filled in the tubing string 22 of cytohormone absorber 20, carry out absorption test.
Experiment one:Test compound type polymeric adsorbent is directed to p-cresol adsorption capacity:
Experimental method:P-cresol method of testings are adsorbed using extracorporal circulatory system:
Testing procedure:
I. filling 100mL resins are preserved in cytohormone absorption tubing string with ethanol (EtOH).
Ii. by ethanol replacement into phosphate buffer solution (PBS, Phosphate-buffered saline).
Iii. solution will be tested with test condition containing p-cresol and help Pu 5 (as schemed using the blood in above-mentioned Fig. 8
Shown in 2) input circulation absorption is carried out into cytohormone absorber 20.
Iv. the 0.5th, be sampled within 1,2,3,4,5 hours.
V. entered using high-effect liquid chromatograph (HPLC, high performance liquid chromatography)
Row analysis sample p-cresol concentration.
Vi. test condition, as shown in table 5:
Table 5
As a result with discussion:According to experimental result, by disclosed herein the cytohormone with compound sorbing material 24
Absorber 20 is 87.29% for p-cresol adsorption rate, more than 65%.In addition, being then to represent that cytohormone is adsorbed in table 6
The result of clearance rate of the device 20 for absorption p-cresol obtained by different sample times.
Table 6
Meanwhile, it can also be obtained in Fig. 8, when the adsorption time increase of cytohormone absorber 20, cytohormone is inhaled
Adnexa 20 is higher for p-cresol clearance rate.
Experiment two:Cytohormone, endotoxin (endotoxin), albumin (albumin) absorption test.The mesh of this experiment
Be adsorption capacity of the test cell hormone absorber 20 for various materials to be tested is come with cardiopulmonary Bypass.
Experimental method:The compound sorbing materials 24 (as shown in Figure 1) of 100mL are filled in the pipe of cytohormone absorber 20
In post 22 (as shown in Figure 1), substances will be added in advance with side Pu (not represented in figure) of wriggling, such as temperature is 37 DEG C of pig blood
Slurry, in the tubing string 22 of circulation conveying to cytohormone absorber 20 so that compound polymeric adsorbent 24 in tubing string 22 is inhaled
Adhesion test material (temperature is 37 DEG C of Swine plasma).Wherein, circulation time is not less than 2 hours, and test pig blood is sampled afterwards
The change in concentration of substances in slurry.
I. cardiopulmonary Bypass:
The situation of Clinical practice is copied, extracorporeal circulation apparatus is set, to emulate the situation that cytohormone is adsorbed in blood plasma.
Wherein, the setting of each condition such as flow velocity, plasma volume, resin demand etc. of extracorporeal circulation apparatus, according to Clinical practice
Situation is set.
Experimental procedure:
A. prepared by Swine plasma:
1. take addition 1mL heparin sodium injections (heparin sodium) (5000i.u./ml- in every 400mL pigs whole blood
Heparin sodium) as anticoagulant.
2. the speed by pig whole blood using rotating speed as 3500rpm is centrifuged at least 20 minutes, wait to take out after standing
Supernatant liquid, and in 4 DEG C of preservations.Herein it is noted that before the experiment, adding after cytohormone, being heated
To 37 DEG C ± 2 DEG C, and insulation is used.
B. vitro Adsorption is tested:
I. the compound polymeric adsorbents of 100mL are filled in cytohormone absorption tubing string, and carried out clearly with 300mL ethanol
Wash.
Ii. by ethanol replacement into phosphate buffer solution.
Iii. by the 1000mL prepared Swine plasma according to experimental design, predetermined concentration (as listed by table 7 concentration model is added
Enclose) substances.
Iv. the Swine plasma added in advance is carried out with water proof mode of heating being heated to 37 DEG C, and keeps constant temperature.
V. substances will be added in advance with side Pu of wriggling, and temperature is inhaled for 37 DEG C of Swine plasma circulation conveying to cytohormone
Adnexa, the flow velocity of the Swine plasma now inputted is 25mL/min.
Vi. the 0.5th, sampling in 1,2,3,4,5 hours.
Vii. each substances concentration is detected.
Table 7
| Substances | TNF-α | IL-1b | IL-6 | IL-8 | IL-10 | LPS | albumin |
| Experimental concentration pg/ml | 8000 | 1600 | 2000 | 500 | 3333 | 10000 | 3.5g/L |
II. analysis method:
Analyze point-score step as follows:
1. cytohormone ((TNF-α, IL-1 β, IL-6, IL-8, IL-10) concentration analysis:
Cytohormone (TNF-α, IL-1 β, IL-6, IL-8, IL-10) concentration analysis is used into R＆DSYSTEM ELISA
Kit(Catalog No.:DY210、DY201、DY206、DY208、DY217)。
I. by the reagent and standard appended by R＆D SYSTEM (TNF-α, IL-1 β, IL-6, IL-8, IL-10) ELISA Kit
Reagent is diluted to use ratio using being preceding placed at room temperature by product with pure water.
Ii. standard items (TNF-α, IL-1 β, IL-6, IL-8, IL-10standard) are configured to debita spissitudo gradient.
Iii. the 100 tested samples of μ l and (TNF-α, IL-1 β, IL-6, IL-8, IL-10standard) standard are separately added into
Product, are placed in and react 2 hours at room temperature.
Iv. after tested sample and (TNF-α, IL-1 β, IL-6, IL-8, IL-10standard) standard items being removed, with
200 μ l cleaning solution (Wash buffer) is rinsed 4 times.100 μ l detection antibody (Detection antibody) is added,
It is placed in and reacts 2 hours at room temperature.
V. after detecting that antibody is removed, then with 200 μ l cleaning solutions flushing 4 times.Add 100 μ l horseradish peroxidase marks
Remember Streptavidin (Streptavidin-HRP, hereinafter referred to as Streptavidin-HRP) reaction solution, be placed in and react at room temperature
20 minutes.
Vi. after Streptavidin-HRP reaction solutions are removed, rinsed 4 times with 200 μ l cleaning solution.Add 100 μ l
Chromogenic substrate (Chromogen Substrate, hereinafter referred to as Chromogen Substrate) reaction solution, juxtaposition is at room temperature
Reaction 20 minutes, after the stop bath (STOP Solution, hereinafter referred to as STOP Solution) for adding 50 μ l, using wavelength as
450nm light absorption values analyze cytohormone (TNF-α, IL-1 β, IL-6, IL-8, IL-10) concentration.
2. adsorbate total amount is determined:
Take and added cytohormone but not yet carried out the Swine plasma about 5g of adsorption test and carried out after adsorption test
Swine plasma about 5g.Then, 105 DEG C are heated to infrared heater progress respectively, and carry out drying until weight no longer becomes
Turn to only, the part by weight change of solid content before and after record absorption.
Endotoxin 3. (endotoxin) detection method:Utilize endotoxin from E.coli-SIGMA.
Albumin 4. (Albumin) detection method:
Albumin (Albumin) concentration analysis uses Innovative Research, Inc.ELISA Kit (Catalog
No:IRAPKT011)。
I. by Innovative Research, reagent and standard items appended by Inc.ELISA Kit are using being preceding placed in
At room temperature, and by reagent with pure water it is diluted to use ratio.
Ii. albumin standard (Albumin standard) is configured to debita spissitudo gradient.
Iii. the 100 tested samples of μ l and albumin standard (Albumin standard) are separately added into, is placed at room temperature
Reaction 2 hours.
Iv. after removing tested sample and albumin standard, rinsed 4 times with 200 μ l cleaning solutions.Add 100 μ l inspections
Antibody is surveyed, is placed in and reacts 2 hours at room temperature.
V. after detecting that antibody is removed, rinsed 4 times with 200 μ l cleaning solutions.Add 100 μ l Streptavidin-HRP
Reaction solution, is placed in and reacts 20 minutes at room temperature.
Vi. after Streptavidin-HRP reaction solutions are removed, rinsed 4 times with 200 μ l cleaning solutions.Add 100 μ l
Chromogen Substrate reaction solutions, be placed at room temperature react 20 minutes, add 50 μ l STOP Solution it
Afterwards, albumin concentration is analyzed with wavelength 450nm light absorption values.
III. result is with discussing:
1. cytohormone absorber is to the absorption result of each cytohormone:
Below be disclosed herein cytohormone absorber for each cytohormone absorption result, it is bright in result
Aobvious learns that adsorption rate is all higher than 65%, because disclosed herein the cytohormone absorber with compound sorbing material 24
20 can effectively adsorb for septicemia relevant cell hormone.Table 8 represents cytohormone absorber to various cytohormones
Clearance rate %.
Table 8
In addition, it is further by the clearance rate listed by table 8, by various cytohormones in different sample times
And clearance rate is represented with adsorption curve figure respectively, wherein Fig. 9 represents that cytohormone absorber swashs to each cell
Adsorption curve figure, Figure 10 of the Scavenging activity of element represent cytohormone absorber to the adsorption curve figure of IL-1 β Scavenging activity,
Figure 11 represents that cytohormone absorber represents cytohormone absorber pair to adsorption curve figure, Figure 12 of IL-6 Scavenging activity
Adsorption curve figure, Figure 13 of IL-8 Scavenging activity represent adsorption curve of the cytohormone absorber to IL-10 Scavenging activity
Figure and Figure 14 represent adsorption curve figure of the cytohormone absorber to the Scavenging activity of TNF-α.
2. the absorption result of cytohormone absorber induced by endotoxin (endotoxin):
Cytohormone absorber for endotoxin absorption clearance rate up to 43.57%, its result such as table 9, and
Adsorption curve figure of the cytohormone absorber to endotoxin Scavenging activity is represented in Figure 15.
Table 9
3. adsorbate total amount measurement result:
Table 10 obtains the front and rear solid content part by weight change of plasma adsorption and is down to 6.20% by 7.06%.
Table 10
Table 11 is then to represent that cytohormone absorber adsorbs albumin result.
Table 11
Therefore, by table 11 it is known that the cytohormone absorber with compound sorbing material for albumin suction
Attached rate is 13.39%, less than 15%.
In addition, the present invention has also built the functional pig septicemia animal experiment of septicemia treatment blood purification system
Pattern and the septicemia treatment pig septicemia animal examination of blood purification system function and security for completing existing product
Test.The purpose of this experiment is:The functional pig sepsis animal experiment pattern of septicemia treatment blood purification system is built,
With confirm disclosed herein blood purification system effect and security.
Experimental method includes:Blood purification animal (pig) surgical procedure (SOP-EXP-HEM-001) and 2.
Blood purification is tested：Wash kidney machine instrumentation (SOP-EXP-HEM-002).
Experimental condition is made a summary
Animal:Lanyu miniature pig(♀；35±5Kg)；
Chemical inducedsepsis:iv injected with LPS(1μg/kg for2hr)；
Product (existing product):(Manufacturer:BellcoSrl,Mirandola,Italy；
Material:hydrophobic styrene resin；Surface area:700m2/g)；
Blood sampling(per 30min)；
Hemodynamic monitoring(per 1hr):Systolic Pressure,Diastolic Pressure,
Mean Arterial Pressure,Heartbeat,and SpO2Analysis:Endotoxin；TNF-α；IL-6.
As a result with discussion：
1. hemodynamic monitoring result:
Figure 16 represents synchronously to carry out the result of hemodynamic monitoring during zoopery, in Figure 16 it is known that
There is drop in blood pressure and the increased situation of heartbeat after surgery in each group animal, meet septicemia clinic table disease and blood oxygen concentration all
Stable state (>=90%) is maintained, Vital status is stable, shows with current LPS dosage (1 μ g/kg) induced animal septicemia
Pattern, animal can't be caused to suffer a shock and dead.
2. endotoxin and cytohormone concentration monitor result:
Non- endotoxin injection and animal experiment (the Hemopurification alone groups) result for only carrying out blood purification
It has been shown that, as shown in figure 17.Endotoxin is with cytohormone concentration without obvious change in animal body, and display experiment uses existing production
The doughnut and resin continous way filtering element (cartridge) system of product do not result in influence to this zootype, and this blood purification system is without safety
Doubt.Contained according to document, septicemia is in its process, systemic inflammation reaction syndrome (SIRS；systemic
Inflammatory response syndrome) the anti-inflammatory reaction of compensatory, this process exotic mediums before this will be triggered
Cell is stimulated, the phenomenon that a variety of different cytohormones cause excessive buildup IL-6, IL-1 β and TNF-α is disengaged, compares this reality
Test from the point of view of the data that septicemia (LPS alone groups) is produced with chemical induction animal, endotoxin and cytohormone in animal body
Significant increase is all presented in concentration after LPS is given, and TNF-α about peaked at 1.5 to 2 hours, and IL-6 is then small from 1
When after persistently rise, peak within about 5 to 6 hours, this variation tendency is also consistent with the illness of Clinical sepsis, show this move
Thing pattern can definitely trigger septicemia.
In the result of existing product adsorption capacity (L+H groups), endotoxin bulk concentration increase after LPS is given, when stopping
It can be found that the concentration curve descending slope and amplitude that have absorption group are slightly larger than LPS groups, in addition in cytohormone after only inducing
In change, learnt by Figure 18, TNF-α just has obvious increase in dialysis its concentration curve descending slope at initial stage and amplitude, by scheming
19 learn, IL-6 then arrives dialysis later stage bulk concentration and just begun to decline, this trend changed in vivo with TNF-α and IL-6 in itself
Relevant, with the display of current data, the septicemia treatment of existing product has endotoxin with blood purification system and cytohormone is inhaled
Attached ability, only the adsorption capacity of existing product have no significant difference.
Figure 20 is represented in the cytohormone absorber test according to disclosed by invention (L+H (new) group), at present in dynamic
One group of experiment was carried out in object, the cytohormone absorber that this plan of entry evaluation is developed, which has, removes excessive cytohormone
Potentiality.It is follow-up by experiment the effect of carrying out formal to confirm its effect.And table 12 is then the knot for representing absorber adsorption
Really:
Table 12
In accordance with the above, disclosed herein cytohormone absorber with vitro Adsorption experimental test comprising TNF-α,
IL-1 β, IL-6, IL-8, IL-10 clearance rate are above 65%.It is 43.57% (Ying≤30% to adsorb endotoxin ability), and
Adsorbable p-cresol is up to 87.29% (Ying≤65%).In addition, adsorbate total amount result is shown, the absorption of cytohormone absorber
Material is down to 6.20% from 7.06% in blood plasma.The cytohormone absorber adsorbs (Ying≤15% of albumin 13.20% simultaneously).
The preferred embodiments of the invention is the foregoing is only, the interest field of the present invention is not limited to；More than simultaneously
Description, should can understand and implement for the special personage of correlative technology field, thus other without departing from it is disclosed it
The lower equivalent change or modification completed of spirit, should be included in claim.
Claims (10)
1. a kind of blood purification system, it is characterised in that include:
Plasma separator, with first tubing string and the multiple hollow fiber bundles being filled in the first tubing string, the blood plasma point
From device to separate the blood plasma in blood and multiple blood cells；And
Cytohormone absorber, with second tubing string and the compound sorbing material being placed in the second tubing string, the cell
Hormone absorber utilizes the compound sorbing material absorption to receive the blood plasma conveyed by the plasma separator
In the blood plasma partial pathogenic cell hormone to be purified blood plasma.
2. blood purification system as claimed in claim 1, it is characterised in that the blood purification system also includes haemodialysis
Device, the haemodialyser to mixing blood to be dialysed to obtain clean blood, and the blood that mixes is by described
Obtained by after blood cell mixing after purifying blood plasma and being separated via the plasma separator.
3. blood purification system as claimed in claim 1, it is characterised in that the compound sorbing material is by uncharged
Resin and electrically charged anion exchange resin composition.
4. blood purification system as claimed in claim 3, it is characterised in that uncharged resin and electrically charged the moon
The mixing ratio of ion exchange resin is by 20%:80%th, 40%:60%th, 60%:40% and 80%:20% (v/v) is constituted
Group among select.
5. the blood purification system as described in claim 3 or 4, it is characterised in that uncharged resin is poly- (benzene second
Alkene-divinylbenzene) (poly (styrene-divinylbenzene), and chemical structural formula is
6. the blood purification system as described in claim 3 or 4, it is characterised in that the electrically charged anion exchange resin
For poly- (styrene-divinylbenzene) level Four ammonium, Cl types, and chemical structural formula are
7. a kind of blood purification method, it is characterised in that include:
Blood is provided；
The blood is separated to obtain blood plasma and multiple blood cells；
Adsorption step is carried out to the blood plasma, to remove at least one pathogenic cytohormone in the blood plasma, to be purified blood
Slurry；
The purification blood plasma is mixed with the blood cell to form mixing blood；And
The mixing blood is dialysed, to obtain clean blood.
8. blood purification method as claimed in claim 7, it is characterised in that compound adsorption material is utilized in the adsorption step
Material is adsorbed to the blood plasma.
9. blood purification method as claimed in claim 8, it is characterised in that the compound sorbing material includes neutral
Resin and electrically charged anion exchange resin.
10. blood purification method as claimed in claim 8 or 9, it is characterised in that the mixed proportion of the compound material is
20%:80%th, 40%:60%th, 60%:40% with or 80%:20% (v/v).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW105110227 | 2016-03-31 | ||
| TW105110227A TWI595897B (en) | 2016-03-31 | 2016-03-31 | Blood Purification System |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107281572A true CN107281572A (en) | 2017-10-24 |
Family
ID=60095681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610471829.9A Pending CN107281572A (en) | 2016-03-31 | 2016-06-24 | Blood purification system |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN107281572A (en) |
| TW (1) | TWI595897B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111407943A (en) * | 2020-04-25 | 2020-07-14 | 宁波高新区零零七工业设计有限公司 | Virus adsorption separation harmless treatment equipment and treatment method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101041092A (en) * | 2007-04-27 | 2007-09-26 | 高光勇 | Multiple organ dysfunction and support system |
| CN101657224A (en) * | 2007-01-12 | 2010-02-24 | 贝尔科股份责任有限公司 | Polymer resin is used for the purposes of the external removal inflammatory mediator of adsorptivity in the treatment of whole body inflammatory relevant disease |
| CN104379190A (en) * | 2012-11-26 | 2015-02-25 | 甘布罗伦迪亚股份公司 | Liver support system |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040182783A1 (en) * | 2003-03-17 | 2004-09-23 | Walker Kimberly A. | Filter and concentrator device for treatment of blood |
| WO2010073320A1 (en) * | 2008-12-24 | 2010-07-01 | 株式会社Ｒｅｉメディカル | Blood purification device |
| EP2617444B1 (en) * | 2010-09-15 | 2020-07-15 | Asahi Kasei Medical Co., Ltd. | Blood purification device and control method therefor |
| KR101814854B1 (en) * | 2010-12-28 | 2018-01-04 | 도레이 카부시키가이샤 | Medical material and hollow fiber membrane module |
| TWM516978U (en) * | 2015-10-23 | 2016-02-11 | 禾研科技股份有限公司 | Filtration membrane holder |
| CN105214158B (en) * | 2015-11-12 | 2018-06-29 | 珠海健帆生物科技股份有限公司 | Apparatus for purifying blood and blood purification system |
-
2016
- 2016-03-31 TW TW105110227A patent/TWI595897B/en not_active IP Right Cessation
- 2016-06-24 CN CN201610471829.9A patent/CN107281572A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101657224A (en) * | 2007-01-12 | 2010-02-24 | 贝尔科股份责任有限公司 | Polymer resin is used for the purposes of the external removal inflammatory mediator of adsorptivity in the treatment of whole body inflammatory relevant disease |
| CN101041092A (en) * | 2007-04-27 | 2007-09-26 | 高光勇 | Multiple organ dysfunction and support system |
| CN104379190A (en) * | 2012-11-26 | 2015-02-25 | 甘布罗伦迪亚股份公司 | Liver support system |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111407943A (en) * | 2020-04-25 | 2020-07-14 | 宁波高新区零零七工业设计有限公司 | Virus adsorption separation harmless treatment equipment and treatment method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI595897B (en) | 2017-08-21 |
| TW201733625A (en) | 2017-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8771513B2 (en) | Regeneratable filter for extracorporal treatment of liquids containing particles and use thereof | |
| CN100486651C (en) | Multiple organ dysfunction support system | |
| CA1086235A (en) | Continuous removing system of blood substances by extra corporeal circulation | |
| Reiter et al. | In vitro removal of therapeutic drugs with a novel adsorbent system | |
| Atan et al. | Techniques of extracorporeal cytokine removal: a systematic review of the literature | |
| CN111250055B (en) | Chitosan-based blood perfusion adsorbent and application thereof in preparation of blood perfusion device for purifying sepsis blood | |
| CN109107541A (en) | The blood compatibility adsorbent of the dialysis of uremic toxins for protein combination | |
| CN108310503A (en) | A kind of Almightiness type plasma purification system based on centrifugal separation plasma method | |
| Steczko et al. | Cytokines and Endotoxin Removal by Sorbents and Its Application in Push–Pull Sorbent‐Based Pheresis: The Biologic‐DTPF System | |
| CN203507201U (en) | Separating type hemodialysis absorber | |
| WO2006012885A1 (en) | Filter system for treating liquids containing particles using membrane isolation and adsorption | |
| CN107281572A (en) | Blood purification system | |
| US20180093032A1 (en) | Targeted apheresis using binding agents or ligands immobilized on membranes | |
| CN106110423B (en) | Female tire blood group incompatibility adsorbing therapy instrument | |
| EP3563888A1 (en) | Multi-stage blood purification apparatus for removal of toxins | |
| CN201026322Y (en) | Multiple organ functions support system | |
| CN106267407A (en) | Female tire Rh blood group incompatibility blood purifying therapeutical instrument | |
| Teehan et al. | Reprocessed (high-flux) Polyflux® dialyzers resist trans-membrane endotoxin passage and attenuate inflammatory markers | |
| CN106110424A (en) | Female tire Rh blood group incompatibility immunoadsorption therapy instrument | |
| CN203354984U (en) | Plasma exchange adsorption filtration purification system for preparing square plasma storage pond | |
| US20130161247A1 (en) | Apparatus for Blood Purification by Extracorporeal Circulation | |
| CN105727382B (en) | A kind of continous way CRRT machine capability bascules of two tripper | |
| CN205649684U (en) | Discontinuous CRRT machine capacity balancing unit | |
| CN106659834A (en) | System for removing pro-inflammatory mediators as well as granulocytes and monocytes from blood | |
| CN205515732U (en) | Continuous type CRRT machine capacity balancing unit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171024 |
|
| WD01 | Invention patent application deemed withdrawn after publication |